Between 1970 and 1995, the incidence of new NHL cases increased. Between 2007 and 2016, new cases declined by approximately 0.9% per year, and mortality from NHL decreased by 2.2% per year. 3 ...

The FDA granted Fast Track Designation to coramitug for ATTR-CM as it advances in the ongoing phase 3 CLEOPATTRA trial. The US Food and Drug Administration (FDA) has granted Fast Track Designation to ...

The model had an area under the receiver operating characteristic curve of 0.83 in a high-risk subgroup of patients with conditions that mimic ATTR-CM. An artificial intelligence model trained to ...

The high-output heart failure cohort was characterized by an increased frequency of secondary MF and lower baseline hemoglobin levels. Echocardiographic high-output heart failure in patients with ...

In a phase 3 trial, participants taking venglustat demonstrated statistically significant improvement in neurological symptoms compared with those receiving ERT. Sanofi announced that the US Food and ...

Despite a phase 3 trial that narrowly missed its primary endpoint, Sarepta is pursuing traditional approval for the 2 DMD therapies. Sarepta Therapeutics will submit supplemental new drug applications ...

Tryptophan-kynurenine and arginine-polyamine pathways were strongly linked to severe neurotoxicity and poorer outcomes. Metabolomic pathway-based scores outperformed traditional inflammatory protein ...

Benefit with luspatercept persisted in SF3B1-mutated and wild-type disease and at higher variant allele frequencies. Luspatercept demonstrated superior red blood cell transfusion independence and ...

Participants taking 18 mg of nerandomilast experienced a significantly lower risk of acute exacerbation of interstitial lung disease. The US Food and Drug Administration (FDA) has approved ...

Castleman disease’s higher mortality and invasiveness require prompt recognition, while IgG4-ROD’s benign yet recurrent nature supports immunomodulatory therapy and long-term follow-up. Chinese ...

Glycoengineering to reduce fucosylation may improve clinical efficacy for preventing maternal alloimmunization. Afucosylation of anti-D monoclonal antibodies (mAbs) improved antibody-dependent ...

A radiotherapy-sparing approach may be beneficial in vulnerable patients with NF1-associated medulloblastoma. A child with neurofibromatosis type 1 (NF1) was diagnosed with medulloblastoma, which was ...